Pseudohallucinations Associated with Moclobemide

The goal of the multicenter drug surveillance project AMSP (”Arzneimittelsicherheit in der Psychiatrie”) is the monitoring, assessment and analysis of adverse drug reactions (ADR) of psychopharmalogical drugs. We report about a 23 year-old patient with a depressive episode. He developed severe pseudohallucinations under a treatment with moclobemide. The symptoms occur 6 days after starting the medication and decline within two days after stopping moclobemide. The term "pseudohallucinations" is discussed controversially but still of high interest.

References

• 1 Adityanjee B. Clinical significance of pseudohallucinations.  Gen Hosp Psychiatry. 2000;  2 124-126
• 2 Bourgeois J A, Thomas D, Johansen T. et al . Visual hallucinations associated with fluoxetine and sertraline.  J Clin Psychopharmacol. 1998;  18 482-483
• 3 Degner D, Grohmann R, Kropp S. et al . Severe drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.  Pharmacopsychiatry. 2004;  37/S 1 39-45
• 4 Hoffmann W. A case of tranylcypromine-induced hallucination.  Psychiatr Prax. 1993;  20 116
• 5 Isbister G K, Hackett L P, Dawson A H. et al . Moclobemide poisoning: toxicogenetics and occurrence of serotonin toxicity.  Br J Clin Pharmacol. 2003;  4 441-450
• 6 Laux G, Baier D. Qualtiy-monitoring of psychotropic drug therapy in post-marketing surveillance. Results of a drug utilization observation (DUO) study on moclobemide.  Pharmacopsychiatry. 1997;  30 21-27
• 7 Takeshi T. Tricyclic-induced musical hallucinations and states of relative sensory deprivation.  Biol Psychiatry. 1995;  38 192-193
• 8 van der Zwaard R, Polak M A. Pseudohallucinations: A pseudoconcept? A review of the validity of the concept related to associate symptomatology.  Compr Psychiatry. 2001;  42 42-50